Kadmon Announces Pricing Of Initial Public Offering

Published: Jul 27, 2016

NEW YORK--(BUSINESS WIRE)--Kadmon Holdings, Inc. today announced the pricing of its initial public offering of 6,250,000 shares of common stock at $12.00 per share, before underwriting discounts and commissions. Kadmon has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price. Kadmon’s common stock is expected to begin trading on July 27, 2016, on the New York Stock Exchange under the symbol “KDMN”. The offering is expected to close on August 1, 2016, subject to customary closing conditions.

Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering. JMP Securities LLC is acting as lead manager and H.C. Wainwright & Co., LLC is acting as manager for the offering.

A registration statement relating to these securities has been declared effective by the U.S. Securities and Exchange Commission on July 26, 2016. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to the offering may be obtained by contacting Citigroup by mail, c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; or Jefferies LLC by mail at 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877)-821-7388 or by email at prospectus_department@jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kadmon

Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. Kadmon is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.

Kadmon Holdings, Inc.
Ellen Tremaine, Investor Relations

Back to news